StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.01−0.18 (-1.77%)

Close on Nov 19, 2026Market cap $842.05MP/E –Yield –

Corvus Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Corvus Pharmaceuticals

Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Corvus Pharmaceuticals figures

See a number that looks wrong?